# SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

> **NCT00180479** · PHASE3 · COMPLETED · sponsor: **Abbott Medical Devices** · enrollment: 1002 (actual)

## Conditions studied

- Stents
- Coronary Artery Disease
- Total Coronary Occlusion
- Coronary Artery Restenosis
- Stent Thrombosis
- Vascular Disease
- Myocardial Ischemia
- Coronary Artery Stenosis

## Interventions

- **DEVICE:** XIENCE V® Everolimus Eluting Coronary Stent
- **DEVICE:** TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent

## Key facts

- **NCT ID:** NCT00180479
- **Lead sponsor:** Abbott Medical Devices
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2006-12
- **Final completion:** 2011-11
- **Target enrollment:** 1002 (ACTUAL)
- **Last updated:** 2011-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00180479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00180479, "SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00180479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*